Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $16.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2025 earnings at $1.36 EPS, FY2026 earnings at $2.25 EPS, FY2027 earnings at $3.14 EPS and FY2028 earnings at $6.05 EPS.

A number of other analysts have also issued reports on ESPR. StockNews.com upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Trading Up 8.1 %

NASDAQ:ESPR traded up $0.17 during trading hours on Friday, hitting $2.28. The stock had a trading volume of 8,947,091 shares, compared to its average volume of 3,084,196. Esperion Therapeutics has a 1-year low of $0.87 and a 1-year high of $3.40. The business has a 50 day simple moving average of $1.91 and a two-hundred day simple moving average of $2.13. The company has a market cap of $447.39 million, a PE ratio of -3.56 and a beta of 0.96.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. Research analysts expect that Esperion Therapeutics will post -0.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ESPR. Vanguard Group Inc. lifted its holdings in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the period. Bellevue Group AG lifted its holdings in Esperion Therapeutics by 136.5% in the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after purchasing an additional 5,739,800 shares during the period. SG Americas Securities LLC acquired a new stake in Esperion Therapeutics in the first quarter worth about $69,000. Marshall Wace LLP lifted its holdings in Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.